Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 22, Issue SUPPL. 6, 2011, Pages

  Eckel, F ^a   Brunner, T ^b   Jelic, S ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ABDOMINAL RADIOGRAPHY; ADVANCED CANCER; ARTICLE; BILE DUCT CANCER; BILIARY TRACT DRAINAGE; BILIARY TRACT ENDOSCOPY; BILIARY TRACT SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLANGITIS; CHOLECYSTECTOMY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; FOLLOW UP; GALLBLADDER CANCER; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LAPAROSCOPY; LIVER LOBECTOMY; LIVER TRANSPLANTATION; LYMPHADENECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE JAUNDICE; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 80052766009     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr375     Document Type: Article

References (19)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
2. Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg 2008; 247: 104-108.
3. Goetze TO, Paolucci V. Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German Registry. Surg Endosc 2008; 22: 2462-2465.
4. Neuhaus P, Jonas S, Settmacher U et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003; 388: 194-200.
5. Killeen RP, Harte S, Maguire D, Malone DE. Achievable outcomes in the management of proximal cholangiocarcinoma: an update prepared using 'evidence-based practice' techniques. Abdom Imaging 2008; 33: 54-57.
6. de Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378.
7. Takada T, Amano H, Yasuda H et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695.
8. Heimbach JK, Gores GJ, Haddock MG et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004; 24: 201-207.
9. McMasters KM, Tuttle TM, Leach SD et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174: 605-608; discussion 608-609.
10. Laurent S, Monsaert E, Boterberg T et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. Ann Oncol 2009; 20: 1369-1374.
11. Schoppmeyer K, Miethe S, Wiedmann M et al. Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. Am J Clin Oncol 2006; 29: 576-582.
12. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
13. Valle JW, Wasan HS, Palmer DD et al. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). Proc Am Soc Clin Oncol 2009: 27: abstract 4503.
14. Lubner SJ, Mahoney MR, Kolesar JL. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol; 28: 3491-3497.
15. Fuller CD, Dang ND, Wang SJ et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. Radiother Oncol 2009; 92: 249-254.
16. Castaldo ET, Wright Pinson C. Liver transplantation for non-hepatocellular carcinoma malignancy. HPB (Oxford) 2007; 9: 98-103.
17. Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363.
18. Zoepf T, Jakobs R, Arnold JC et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430.
19. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11: 48-54.